
Pelareorep Shows Transformative Survival Data in Advanced Cancers, Pivoting to Registration Studies
Oncolytics Biotech Inc, a clinical-stage immunotherapy company, has announced compelling survival data for its intravenously delivered oncolytic virus immunotherapy, pelareorep (Reolysin), across multiple tumor types, signaling a strategic shift toward …